BioSpace News Archive

Augmedix announced that Joe Marks, Executive Director of the Center for Machine Learning & Health at Carnegie Mellon University, has joined the Augmedix team as the newest board of directors member.

Trillium Therapeutics Inc. announced that it has commenced a public offering of common shares of the Company and Series II Non-Voting Convertible First Preferred Shares of the Company.

Hologic, Inc. announced the release of the Company’s first sustainability report, Making a Unique Difference in the World.

Seneca Biopharma, Inc. announced the closing of the previously announced agreement by several accredited investors to exercise certain warrants to purchase up to an aggregate of 5,555,554 shares of common stock having an exercise price of $2.70 issued by the company on July 30, 2019, at a reduced exercise price of $1.36 per share.

Phase 3 trial achieved its primary endpoint and all secondary endpoints with marked improvement in key indicators of disease

Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary premarket approval application to the U.S. Food and Drug Administration for its myChoice® CDx test to help predict outcomes of women with first-line platinum responsive advanced ovarian cancer treated with GSK’s PARP inhibitor Zejula®.

Ascletis Pharma Inc. announces the approval for ASC22 to conduct clinical trials in chronic hepatitis B patients in China from China’s National Medical Products Administration.

Xenon Pharmaceuticals Inc., a clinical stage biopharmaceutical company, announced the pricing of its underwritten public offering of 3,750,000 common shares pursuant to its existing shelf registration statement at a public offering price of $16.00 per share.

Blueprint Medicines Corporation announced the pricing of an underwritten public offering of 4,710,144 shares of its common stock at a public offering price of $69.00 per share, before underwriting discounts and commissions.

Opsens Inc. held its annual general and special shareholders’ meeting in Quebec City, Canada..